The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Hepatitis Virus, Rheumatic Disease Connection Explored

Hepatitis Virus, Rheumatic Disease Connection Explored

July 14, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
fotovapl/shutterstock.com

fotovapl/shutterstock.com

CHICAGO—Leonard H. Calabrese, DO, professor of medicine at Cleveland Clinic in Ohio, presented on emerging concepts of viral infections and rheumatic disease at the ACR’s State-of-the-Art Clinical Symposium in April. “We are at a pivotal point in rheumatology in understanding the relationship between viruses and rheumatic disease,” began Dr. Calabrese. “It’s a very exciting time.” Dr. Calabrese then discussed hepatitis C (HCV) and hepatitis B viruses (HBV) and their association with rheumatic disease in more detail.

You Might Also Like
  • Hepatitis-C Virus–Associated Arthritis
  • Hepatitis C Virus Infection Associated with Rheumatoid Arthritis
  • Hepatitis Reaction with Rituximab Sparks Drug Safety Alert
Explore This Issue
July 2017
Also By This Author
  • Infiltrating the Disc: Mast Cells & Back Pain

HCV & Rheumatic Disease

Dr. Calabrese described HCV as “a deaccelerating infection.” Although there are 200 million individuals worldwide infected with the virus, he believes that, with the advent of direct-acting anti-virals (DAA), it will soon be possible to abolish HCV infections. DAA treatment is associated with cure rates of 95–100%. Treatment protocols can be as brief as six weeks, causing Dr. Calabrese to enthuse, “This is a curable disease—within a few months. … It’s a whole new deal.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

DAAs have not only changed the medical landscape for patients with HCV, but have also led to the question: How quickly does their immune deficit recover? Unfortunately, according to Dr. Calabrese, there appears to be a long delay.

HCV infection increases the risk for several rheumatologic diseases, but patients who are infected with HCV are most at risk for cryoglobulinemic vasculitis, which manifests with palpable purpura, arthralgia and weakness.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A study presented at the 2016 ACR/ARHP Annual Meeting examined the effect of DAAs on HCV cryoglobulinemic vasculitis.1 It included 35 patients who were prescribed sofosbuvir and daclatasvir. The patients achieved 100% sustained virologic response (SVR) and had a 91% complete clinical response at 12 weeks. However, at 12 weeks, only 50% of patients had a complete immunologic response. These findings build on results from previous studies, which also demonstrated either failure to clear cryoglobulinemic vasculitis or a relapse of cryoglobulinemic vasculitis that appeared independent of virologic relapse.

The 2015 ACR screening recommendations for HCV remain unchanged from the 2008 recommendations.2 The guidelines suggest screening those at risk for HCV infection only prior to treatment with methotrexate/leflunomide. Dr. Calabrese counters, however, that HCV as a comorbidity for rheumatic disease now serves as an opportunity to bring HCV-infected patients into a circle of care.

The treatment goal for a patient who is positive for HCV is to first cure the HCV infection and then manage the autoimmune diseases traditionally. Thus, rheumatologists should screen for HCV, and if the patient tests positive, refer them to a good hepatologist for treatment. If the patient does not respond to DAA, then alternative and older treatment strategies apply.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: 2017 State of the Art Clinical Symposium, AC&R, American College of Rheumatology, comorbidity, connection, direct-acting anti-virals, drug therapy, hepatitis, Research, rhematic disease, rheumatology, symptom, Treatment, Vasculitis, virusIssue: July 2017

You Might Also Like:
  • Hepatitis-C Virus–Associated Arthritis
  • Hepatitis C Virus Infection Associated with Rheumatoid Arthritis
  • Hepatitis Reaction with Rituximab Sparks Drug Safety Alert
  • ACR 2013 State-of-the-Art Clinical Symposium: Diagnosis and Management of Vasculitis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.